# AstraZeneca’s Forxiga approved in the EU for heart failure

- Link: https://www.directorstalkinterviews.com/astrazenecas-forxiga-approved-in-the-eu-for-heart-failure/412935385
- Published: 2020-11-05T07:29:14+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Forxiga_ (dapagliflozin) has been approved in the European Union (EU) for the treatment
of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults
with and without type-2 diabetes (T2D).

Heart failure (HF) is a life-threatening chronic disease that prevents the heart
from pumping sufficient levels of blood around the body. It affects 15 million people
in the EU, at least half of whom have a reduced ejection fraction,^(1-3) which occurs
when the left ventricle muscle is not able to contract adequately and therefore 
expels less oxygen-rich blood into the body.^(4-6)

The approval by the European Commission is based on positive results from the landmark
DAPA-HF Phase III trial, published in The New England Journal of Medicine.^(7) It
follows the recommendation for approval by the Committee for Medicinal Products 
for Human Use of the European Medicines Agency.

> **John McMurray, MD, Cardiovascular Research Centre, Institute of Cardiovascular
> and Medical Sciences, University of Glasgow, UK, said: **“Today’s approval provides
> physicians with a completely novel treatment for heart failure with reduced ejection
> fraction, not only improving symptoms and reducing hospital admissions, but also
> increasing survival in this life-threatening condition.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said**: “With
> this approval of _Forxiga_, we can redefine the standard of care for millions 
> of people in the EU living with heart failure. We are another step closer to achieving
> our ambition of preventing or treating heart failure by providing a treatment 
> that can significantly reduce cardiovascular death and hospitalisation.”

_Forxiga_ is the first sodium-glucose co-transporter-2 (SGLT2) inhibitor to have
shown a statistically significant reduction in the risk of the composite of cardiovascular(
CV) death or worsening of HF events, including hospitalisation for HF (hHF). The
DAPA-HF Phase III trial demonstrated that _Forxiga_, in addition to standard of 
care, reduced the risk of the composite outcome versus placebo by 26% and both components
of the primary composite endpoint contributed benefit to the overall effect. In 
the DAPA-HF Phase III trial, the safety profile of _Forxiga_ was consistent with
the well-established safety profile of the medicine. During the trial, one CV death
or hHF or an urgent visit associated with HF could be avoided for every 21 patients
treated.

_Forxiga_ (known as _Farxiga_ in the US) is approved in the US for the treatment
of patients with HFrEF and is currently under review in Japan and in several over
countries around the world.

_Forxiga_ is advancing cardiorenal prevention as science continues to identify the
underlying links between the heart, kidneys and pancreas. DAPA-HF is part of DapaCare,
a robust clinical trial programme to assess the potential CV and renal benefits 
of _Forxiga_. The programme has also explored the treatment of patients with chronic
kidney disease (CKD) in the ground-breaking DAPA-CKD Phase III trial. Additionally,
_Forxiga_ is currently being tested for HF patients with preserved ejection fraction(
HFpEF) in the DELIVER Phase III trial with data anticipated in the second half of
2021.

**Heart failure**

HF affects approximately 64 million people worldwide (at least half of whom have
a reduced ejection fraction), including 15 million in the EU and six million in 
the US.^(2-3,8) It is a chronic disease where half of patients will die within five
years of diagnosis.^(9) There are two main categories of HF related to ejection 
fraction (EF), a measurement of the percentage of blood leaving the heart each time
it contracts: HFrEF and HFpEF.^(7) HFrEF occurs when the left ventricle muscle is
not able to contract adequately and therefore, expels less oxygen-rich blood in 
to the body.^(5,6) HF remains as fatal as some of the most common cancers in both
men (prostate and bladder cancers) and women (breast cancer).^(10) It is the leading
cause of hospitalisation for those over the age of 65 and represents a significant
clinical and economic burden.^(11)

**DAPA-HF**

DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) is an
international, multi-centre, parallel-group, randomised, double-blinded Phase III
trial in 4,744 patients with heart failure and reduced ejection fraction (LVEF ≤
40%), with and without T2D, designed to evaluate the effect of _Forxiga _10mg, compared
with placebo, given once daily in addition to standard of care. The primary composite
endpoint was time to the first occurrence of a worsening heart failure event (hospitalisation
or equivalent event; i.e. an urgent heart failure visit), or cardiovascular death.
The median duration of follow-up was 18.2 months.

**_Forxiga_**** **

_Forxiga _(dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor 
indicated in adults for the treatment of insufficiently controlled T2D as both monotherapy
and as part of combination therapy as an adjunct to diet and exercise to improve
glycaemic control, with the additional benefits of weight loss and blood-pressure
reduction.

_Forxiga_ has been evaluated in patients with CKD in the Phase III DAPA-CKD trial,
with the full results announced in August 2020 demonstrating that _Forxiga_ met 
all primary and secondary endpoints, providing overwhelming efficacy. _Forxiga_ 
is currently being tested for patients with HF in the DELIVER (HF with preserved
ejection fraction, HFpEF) and DETERMINE (HFrEF and HFpEF) Phase III trials. _Forxiga_
will also be tested in patients without T2D following an acute myocardial infarction(
MI) or heart attack in the DAPA-MI trial – a first of its kind, indication-seeking,
registry-based randomised controlled trial. _Forxiga_ has a robust programme of 
clinical trials that includes more than 35 completed and ongoing Phase IIb/III trials
in more than 35,000 patients, as well as more than 2.5 million patient-years’ experience.

**AstraZeneca in CVRM**

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s 
three therapy areas and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the heart, kidneys
and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs
and improve outcomes by slowing disease progression, reducing risks and tackling
comorbidities. The Company’s ambition is to modify or halt the natural course of
CVRM diseases and potentially regenerate organs and restore function, by continuing
to deliver transformative science that improves treatment practices and cardiovascular
health for millions of patients worldwide.

Share on:
